Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Diagnostics Research Group

Neither a doctor nor a teaching hospital

Research payments

$2,423,836

645 payments

Through program year 2025, Diagnostics Research Group is reported as receiving $2,423,836 in research payments, across 645 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $31,962 157
2024 Research $36,847 10
2023 Research $164,375 11
2022 Research $416,810 8
2021 Research $552,263 47
2020 Research $362,591 185
2019 Research $858,989 227

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $1,720,026 326 payments
  2. Pfizer Inc. $291,677 59 payments
  3. Boehringer Ingelheim International GmbH $198,263 177 payments
  4. Shionogi Inc $81,186 16 payments
  5. Regeneron Pharmaceuticals, Inc. $52,069 1 payment
  6. Teva Pharmaceuticals USA, Inc. $33,938 10 payments
  7. Boehringer Ingelheim Pharma GmbH & Co.KG $31,959 15 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $7,571 12 payments
  9. Ironwood Pharmaceuticals, Inc $3,418 2 payments
  10. Boehringer Ingelheim France S.A.S. $3,413 25 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1,Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults $418,250 4 payments
  2. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine with a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older. $412,562 5 payments
  3. Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age $307,381 25 payments
  4. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE $173,847 12 payments
  5. Hepatic Impairment Study $143,018 5 payments
  6. A Phase 3 Randomized Observerblinded Study to Evaluate the Immunogenicity Safety and Tolerability of 2 Doses Compared to 3 Doses of Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $112,645 32 payments
  7. A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live-Attenuated Tetravalent Dengue Vaccine V181 in Flavivirus-Na ve and Flavivirus-Experienced Healthy Adults $112,000 24 payments
  8. Phase III Lot Consistency Trial $110,585 15 payments
  9. Evaluation of S-600918 in Adults With Refractory Chronic Cough $81,186 16 payments
  10. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 One Year Later in Healthy Adults 50 Years of Age or Older PNEU-PATH $67,830 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record